Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Late Boost Strategies With IHV01 and A244 in RV306 Participants
NCT04658667Phase 1Completed
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Feb 2022
- Primary completion
- Jul 2024
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IHV01 and A244-rgp120 in human immunodeficiency virus infection (HIV) (5 arms), sponsored by U.S. Army Medical Research and Development Command. Primary endpoints: Number of Participants with Local and Systemic Reactions and Incidence of Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest. Started Feb 2022; status: completed.
02
Drugs
IHV01A244-rgp120
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04658667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04658667.